Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy

Michael J. Brumlik*, Benjamin J. Daniel, Reinhard Waehler, David T. Curiel, Francis J. Giles, Tyler J. Curiel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Many agents used to treat cancer are toxic to normal tissues. Thus, treatments delivering drug specifically to tumour, while minimising exposure to normal tissue, may be advantageous over non-targeted treatments. The exquisite specificity of the immune system has been used successfully to help develop targeted anticancer agents. The most common (and successful) tissue-specific targeting strategies rely on antibody conjugates, but additional approaches, including targeting through cytokines, peptides and recombinant viruses, have also been used successfully. This review summarises the agents exploiting the immunological principles of target specificity to help maximise delivery to tumour while minimising collateral damage to normal tissues. Such targeted molecules are collectively referred to as immunoconjugates.

Original languageEnglish (US)
Pages (from-to)87-103
Number of pages17
JournalExpert Opinion on Drug Delivery
Volume5
Issue number1
DOIs
StatePublished - Jan 2008

Keywords

  • Cancer
  • Cytotoxin
  • Immunoconjugate
  • Targeted drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy'. Together they form a unique fingerprint.

Cite this